{
  "ticker": "PTX",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02974367",
  "id": "02974367",
  "pages": 10,
  "price_sensitive": true,
  "date": "20250730",
  "time": "0941",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250730/pdf/06m9j4r6c6y386.pdf",
  "summary": "### **Material Information Summary (ASX: PTX) \u2013 June 2025 Activities Report & Appendix 4C**  \n\n#### **Key Highlights (Operations/Clinical Updates)**  \n- **FDA Fast Track Designation** granted for PTX-100 in relapsed/refractory **mycosis fungoides** (subtype of CTCL), enabling accelerated development.  \n- **First patient dosed** in randomized **Phase 2a trial** for PTX-100 in CTCL (target: 40 patients across 16 global sites).  \n- **Cell Therapy Progress**: Continued development of **OmniCAR** and **CellPryme-M** platforms, with new collaborations underway.  \n\n#### **Financials (Appendix 4C)**  \n- **Cash balance (30 June 2025)**: **$6.9M** (down from $10.2M in March 2025).  \n- **Net operating cash outflow**: **$3.3M** (R&D/clinical spend: $2.2M).  \n- **Share Purchase Plan (SPP)**: Raised **$6.8M** (closed 25 July 2025).  \n- **Trading Halt (29 July 2025)**: For a **follow-on Placement** to professional investors.  \n\n#### **Valuation/Capital Impact**  \n- Fast Track status and Phase 2a progress may enhance PTX-100\u2019s commercial viability.  \n- SPP + Placement proceeds to fund clinical trials; liquidity extended post-quarter.  \n\n**Omitted**: Director appointment, non-material operational details.",
  "usage": {
    "prompt_tokens": 5934,
    "completion_tokens": 334,
    "total_tokens": 6268,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-07-29T23:54:31.677067"
}